MYELODYSPLASTIC SYNDROMES (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood disorder drug luspatercept gets Long-Term safety review
Disease control Recruiting nowThis study follows about 665 people with myelodysplastic syndromes, beta-thalassemia, or myelofibrosis who have already taken luspatercept in earlier trials. Researchers want to see how safe the drug is over many years by tracking side effects, disease progression, and survival. …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for rare MDS: targeted drug ivosidenib takes on standard therapy
Disease control Recruiting nowThis study is for people with a rare form of myelodysplastic syndromes (MDS) that has a specific genetic change called IDH1 mutation. Participants have not had prior treatment with certain drugs. They will be randomly assigned to receive either ivosidenib (a daily pill) or azacit…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for leukemia patients? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug cocktail aims to tame deadly transplant side effect
Disease control Recruiting nowThis phase 2 trial tests whether adding two drugs, ruxolitinib and abatacept, to standard transplant care can prevent graft-versus-host disease (GVHD) in 60 patients with high-risk myeloid cancers like AML and MDS. Participants receive a stem cell transplant from a partially matc…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug could help High-Risk patients get Life-Saving transplants
Disease control Recruiting nowThis early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New cord blood transplant recipe aims to beat tough blood cancers
Disease control Recruiting nowThis study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 15:21 UTC